Bone Biologics Co. (NASDAQ:BBLG) Short Interest Up 562.5% in July

Bone Biologics Co. (NASDAQ:BBLG) was the recipient of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 5,300 shares, a growth of 562.5% from the June 30th total of 800 shares. Based on an average daily volume of 835,900 shares, the days-to-cover ratio is presently 0.0 days. Approximately 1.0% of the shares of the stock are sold short.

Bone Biologics Price Performance

Shares of BBLG stock traded down $0.10 during trading hours on Friday, reaching $1.99. 459,317 shares of the stock were exchanged, compared to its average volume of 2,649,135. The company’s 50-day moving average price is $1.40 and its 200-day moving average price is $2.20. Bone Biologics has a 12-month low of $1.00 and a 12-month high of $11.76.

Bone Biologics (NASDAQ:BBLG) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($1.31) EPS for the quarter, beating the consensus estimate of ($7.60) by $6.29. Equities research analysts anticipate that Bone Biologics will post -5.32 earnings per share for the current year.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.